MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.

A single nucleotide polymorphism (SNP309) of MDM2 causes elevated MDM2 levels and an attenuation of p53 function. The aim of the present study was to examine the clinical relevance of the MDM2 SNP309 in ovarian cancer.MDM2 SNP309 genotype was analyzed in 198 patients with primary ovarian cancer. MDM2 expression was investigated using immunohistochemistry. A functional yeast-based assay and subsequent sequencing were performed to determine p53 mutational status. Of the patients, 44.4% (88 of 198) exhibited the common variant (T/T), 40.9% (81 of 198) the heterozygous variant (T/G) and 14.7% (29 of 198) the homozygous variant (G/G) MDM2 SNP309 genotype. MDM2 SNP309 was not associated with p53 mutational status, MDM2 expression, clinicopathological parameters or prognosis. In patients with the T allele (T/T and T/G genotype), p53 wild type carcinomas were associated with significantly improved recurrence-free (p<0.001) and overall survival (p<0.001) as compared to p53 mutant carcinomas. In contrast, p53 mutational status did not possess prognostic relevance in G/G carriers. A possible functional impairment of the p53 pathway caused by the G/G genotype of the MDM2 SNP309 may modify the association between p53 mutational status and prognosis in ovarian cancer.

[1]  T. Aas,et al.  Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel , 2011, PloS one.

[2]  B. Kong,et al.  MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis , 2011, Human Cell.

[3]  Long Yu,et al.  MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis. , 2011, Archives of medical research.

[4]  S. Noda,et al.  Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer , 2009, Human Cell.

[5]  Arnold J Levine,et al.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. , 2010, Cancer cell.

[6]  H. Taubert,et al.  MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation , 2010, Pancreas.

[7]  Hung-Ming Wang,et al.  Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. , 2009, Oral oncology.

[8]  L. Kadouri,et al.  Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations , 2009, BMC Cancer.

[9]  R. Zhou,et al.  Association of p73 and MDM2 Polymorphisms With the Risk of Epithelial Ovarian Cancer in Chinese Women , 2008, International Journal of Gynecologic Cancer.

[10]  Jun Yong Park,et al.  MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2008, Carcinogenesis.

[11]  B. Vojtesek,et al.  MDM2SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk , 2008, Oncology.

[12]  R. Heist,et al.  Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk , 2008, International journal of cancer.

[13]  S. Kondo,et al.  Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma , 2008, Acta oto-laryngologica.

[14]  S. Hauptmann,et al.  Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival , 2008, Clinical Cancer Research.

[15]  R. Yarden,et al.  MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent , 2008, Breast Cancer Research and Treatment.

[16]  K. Hemminki,et al.  MDM2 SNP309 and cancer risk: a combined analysis. , 2007, Carcinogenesis.

[17]  R. Dahiya,et al.  MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[18]  N. Socci,et al.  A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer , 2007, Clinical Cancer Research.

[19]  Rochelle L. Garcia,et al.  Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas , 2007, Genes, chromosomes & cancer.

[20]  Y. Hirooka,et al.  MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Eccles,et al.  No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.

[22]  Julie E Goodman,et al.  Association of breast cancer outcome with status of p53 and MDM2 SNP309. , 2006, Journal of the National Cancer Institute.

[23]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[24]  D. Eccles,et al.  Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers , 2006, BMC Cancer.

[25]  D. Gürel,et al.  p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis. , 2005, Gynecologic oncology.

[26]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[27]  R. Zeillinger,et al.  Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo , 2004, Cancer Research.

[28]  G. Jayson,et al.  p53 and related proteins in epithelial ovarian cancer. , 2000, European journal of cancer.

[29]  J. Nesland,et al.  Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.